{"database":"JPOST Repository","file_versions":[{"headers":{"Content-Type":["application/json"]},"body":{"files":{"Xlsx":["https://storage.jpostdb.org/JPST002203/files/F004108_desmoid_FDR1%25.xlsx"],"Raw":["https://storage.jpostdb.org/JPST002203/files/211215_%2334_desmoid_7_500nL.raw","https://storage.jpostdb.org/JPST002203/files/211215_%2329_desmoid_2_500nL.raw","https://storage.jpostdb.org/JPST002203/files/211215_%2331_desmoid_4_500nL.raw","https://storage.jpostdb.org/JPST002203/files/211215_%2332_desmoid_5_500nL.raw","https://storage.jpostdb.org/JPST002203/files/211215_%2330_desmoid_3_500nL.raw","https://storage.jpostdb.org/JPST002203/files/211215_%2333_desmoid_6_500nL.raw"],"Mgf":["https://storage.jpostdb.org/JPST002203/files/211215_desmoid.mgf"]},"type":"primary"},"statusCode":"OK","statusCodeValue":200}],"scores":null,"additional":{"omics_type":["Proteomics"],"submitter":["Masahiro Aoki, Teruaki Fujishita"],"species":["Mus Musculus (mouse)"],"full_dataset_link":["https://repository.jpostdb.org/entry/JPST002203"],"submitter_affiliation":["Nagoya University"],"sample_protocol":[""],"repository":["jPOST"],"data_protocol":[""],"pubmed_abstract":["Desmoid tumors (DTs), also called desmoid-type fibromatoses, are locally aggressive tumors of mesenchymal origin. In the present study, we developed a novel mouse model of DTs by inducing a local mutation in the Ctnnb1 gene, encoding β-catenin in PDGFRA-positive stromal cells, by subcutaneous injection of 4-hydroxy-tamoxifen. Tumors in this model resembled histologically clinical samples from DT patients and showed strong phosphorylation of nuclear SMAD2. Knockout of SMAD4 in the model significantly suppressed tumor growth. Proteomic analysis revealed that SMAD4 knockout reduced the level of Cysteine-and-Glycine-Rich Protein 2 (CSRP2) in DTs, and treatment of DT-derived cells with a TGF-β receptor inhibitor reduced CSRP2 RNA levels. Knockdown of CSRP2 in DT cells significantly suppressed their proliferation. These results indicate that the TGF-β/CSRP2 axis is a potential therapeutic target for DTs downstream of TGF-β signaling."],"pubmed_title":["TGF-β signaling promotes desmoid tumor formation via CSRP2 upregulation."],"pubmed_authors":["Li Yu Y, Fujishita Teruaki T, Mishiro-Sato Emi E, Kojima Yasushi Y, Niu Yanqing Y, Taketo Makoto Mark MM, Urano Yuya Y, Sakai Tomohisa T, Enomoto Atsushi A, Nishida Yoshihiro Y, Aoki Masahiro M"],"name_synonyms":["Mus musculus, Laboratory Mice., House, Mus, Laboratory, Swiss, mice, proteomic analysis, Mus domesticus, mouse, Mus musculus domesticus, Swiss Mouse, Mouse, House Mice, Swiss Mice, house mouse, Mice, Laboratory Mouse, House Mouse, domesticus"],"pubmed_abstract_synonyms":["MGC130048, 2-(4-(1, SMAD family member 4, Ribonucleic, SMAD family member 2, Materials, E 920, smad-2, Laboratory, Mus domesticus, Subcutaneous Injections, postnatal development, tamoxifene, 474, 2-Diphenyl-1-butenyl)phenoxy)-N, ted, A4, Apo-Tamox, growth and development, Tomaxithen, Tumor, House Mouse, phosphorylation, tamoxifen, Mutations, 1-para-beta-Dimethylaminoethoxyphenyl-trans-1, Crisafeno, Mesc, madh4, 2-amino-3-mercaptopropanoic acid, Cystein, 2-diphenyl-1-butenyl)phenoxy)-N, Catnb, Non Polyadenylated, RNA Gene Products, AI115593, Glycine-rich protein, hSMAD2, MADH2, treatment, gamma sarcoglycan, hSMAD4, C, ctnnb1, tamoxifenum, MADH4, hydroxy, XSmad4alpha, APDGFR, HYDROXY GROUP, cisteina, Ethanamine, JV18-1, C2, Tamoxifen Citrate, JV18, hypoplasia, Swiss Mice, trans-Tamoxifen, (Z)-2-(4-(1, tamoxifeno, anon-EST:Posey121, Mothers against DPP homolog 4, Tamoxifen, Mothers against DPP homolog 2, Deletion target in pancreatic carcinoma 4 homolog, disease management, Therapies, gamma-sarcoglycan, Malignancies, house mouse, Half Cystine, Bfc, Tumors, hydroxyl group, 7120426M23Rik, Therapy, l(3)12m-137, N-dimethylethanamine, Citrate, Zinc Cysteinate, ribose nucleic acid, CRP2, SG-gamma, mouse, ribonucleic acids, armadillo, Cys, beta-catenin, AW551867, Subcutaneous, 1-p-beta-Dimethylaminoethoxyphenyl-trans-1, Nolvadex, Benign, N-dimethyl-, Soltamox, dSMAD2, Diemon, Ribonukleinsaeure, l(1)G0348, DSMAD2, Crp2, Genetic Materials, XSmad2, pentosenucleic acids, sarcoglycan, Ribonucleic acids, Pdgfr-2, dSmad2, (2R)-2-amino-3-sulfanylpropanoic acid, dSmad4, Genetic Material, hMAD-2, PDGFR-2, Mus musculus, Acid, DTSF, ICI-46, GRP, -OH, growth pattern, mMad2, Mad-related protein 2, mice, Xsmad4, non-developmental growth, Swiss Mouse, Benign Neoplasms, INSDC_feature:gene, L-Cysteine, gamma (35kDa dystrophin-associated glycoprotein), Treatments, dsmad2, L-Cystein, domesticus, (Z)-2-(para-(1, Malignant Neoplasms, AW743858, Zitazonium, DMDA, Patient, antagonists and inhibitors, Material, 35kD dystrophin-associated glycoprotein, Cells, JIP, AW047313, Cistron, Mouse, other neoplasm, Cysteine Hydrochloride, SGCG_HUMAN, DmelCG1775, Stromal, MADR2, Neoplasms, jip, Benign Neoplasm, L-Zystein, Gene, ICI46, stalk, Hegfl, tmp, PRO2286, Malignant, TYPE, DAGA4, Novaldex, LMO5, HEGFL, ICI 47699, reduced, House, Injection, Stromal Cell, SMAD 4, l(3)SG36, 35DAG, Gene Products, Mus musculus domesticus, SMAD 2, CG2262, tiny, Half-Cystine, MAM, gamma-SG, ctnnb, SCG3, Mice, MYHRS, DSmad2, study, medea, Genetic, Malignancy, Swiss, ICI-47699, Smad-2, L Cysteine, E-920, 2-diphenylbut-1-ene, PDGFR2, smad4, smad2, hydroxy group, inhibiteur, Hcys, Madr2, CD140a, E(zen)3, culm, RHEPDGFRA, SMAD2, Non-Polyadenylated RNA, Neoplasias, SMAD4, MAD homolog 2, OK/SW-cl.35, MAD homolog 4, inhibidor, CYSTEINE, Clients, Smad2, FREE CYSTEINE, SmLIM, SmLim, Smad4, (2R)-2-amino-3-mercaptopropanoic acid, CD140A, single organism signaling., Cancer, small, DmelCG2262, inhibitors, RNA, Malignant Neoplasm, 35 kDa dystrophin-associated glycoprotein, axis, Madh2, Phosphorylations, dpc4, l(3)11m-254, inhibitor, Madh4, RNS, D18Wsu70e, Cistrons, ICI47699, Client, Cell, SGCG, LGMD2C, development, CTNNB, ICI-46474, Mus, yeast nucleic acid, MED, proteomic analysis, ICI 46, Neoplasm, xsmad4a, PDGFACE, Sad, Subcutaneous Injection, CG1775, Zystein, ICI46474, antagonists, DTS, Dts, ribonucleic acid, DTR, Dtr, MRD19, (Z)-, DMDA1, underdeveloped, 2-amino-3-sulfanylpropanoic acid, med, N-dimethylamine, Non Polyadenylated RNA, postnatal growth, Non-Polyadenylated, L-2-Amino-3-mercaptopropionic acid, House Mice, (R)-2-amino-3-mercaptopropanoic acid, sad, Cancers, Ribonucleic Acid, l(3)SG70, 2-Amino-3-mercaptopropionic acid, Laboratory Mice, SMOX, Deletion target in pancreatic carcinoma 4, signalling process, Therapeutic, SCARMD2, hydroxyl, E920, Treatment, ICI 46474, smox, l(3)XIIm137, growth, Laboratory Mouse, Neoplasia, DPC4"],"pubmed_title_synonyms":["single-organism biosynthetic process, Malignant Neoplasm, Malignancy, Upregulation, Receptor Up-Regulation, Neoplasms, CRP2, Benign Neoplasm, Up-Regulation (Physiology), Benign Neoplasms, Cancers, Tumor, Malignant, Malignant Neoplasms, Neoplasias, AW551867, LMO5, Benign, signalling process, Up Regulation., Neoplasm, Crp2, SmLIM, SmLim, Malignancies, other neoplasm, Neoplasia, single organism signaling, multicellular organismal biosynthetic process, Cancer, Tumors"],"description_synonyms":["l(3)12m-137, 3.4.22.-, SMAD family member 4, DmelCG1775, Laboratory, Mus domesticus, jip, CASP14, mouse, dpc4, l(3)11m-254, mini-ICE, armadillo, Madh4, CASP-14, D18Wsu70e, PRO2286, House Mouse, beta-catenin, CTNNB, House, Mus, Mesc, SMAD 4, MED, l(3)SG36, Mini-ICE, proteomic analysis, madh4, Mus musculus domesticus, xsmad4a, Catnb, ctnnb, dSmad4, Mice, MYHRS, CG1775, Mus musculus., hSMAD4, Mus musculus, MRD19, ctnnb1, MADH4, medea, XSmad4alpha, Caspase-14 subunit p10, Swiss, Xsmad4, med, mice, smad4, Swiss Mouse, House Mice, Swiss Mice, Caspase-14 subunit p19, l(3)SG70, MICE, E(zen)3, Laboratory Mice, domesticus, AW743858, SMAD4, Deletion target in pancreatic carcinoma 4, OK/SW-cl.35, MAD homolog 4, anon-EST:Posey121, Mothers against DPP homolog 4, Deletion target in pancreatic carcinoma 4 homolog, JIP, Smad4, Mouse, l(3)XIIm137, Laboratory Mouse, DPC4, Bfc"],"additional_accession":[]},"is_claimable":false,"name":"Proteomic analysis of desmoid tumors in a novel mouse model.","description":"Proteomic analysis was performed on desmoid tumors developed in Ctnnb1 or Ctnnb1/Smad4 compound mutant mice.","dates":{"publication":"Sun Jul 07 00:00:00 BST 2024"},"accession":"PXD043079","cross_references":{"TAXONOMY":["10090"],"pubmed":["38041233"]}}